Duyuru • Jul 24
Terra Innovatum Global N.V. Requests U.S. Nuclear Regulatory Commission to Initiates Preapplication Readiness Review to Support Solo Construction Permit Application Terra Innovatum Global N.V. (Terra or the Company), a developer of advanced micro-modular nuclear reactors, announced that it has requested that the U.S. Nuclear Regulatory Commission (NRC) conduct a voluntary preapplication readiness review of the Company's planned SOLO Micro-Modular Reactor (MMR) Construction Permit Application. The initiative is intended to align Terras licensing work with its previously communicated objective to submit the SOLO Construction Permit Application in 2026 for commercialization in 2028. The readiness review is intended to support Terra's planned SOLO Construction Permit Application submission in 2026 by enabling NRC staff to review draft safety and environmental documentation in advance of a formal application submittal. Through this process, Terra expects NRC staff to identify technical, regulatory and administrative observations early, strengthening the quality of the application, supporting its accelerated parallel construction permit and operating license strategy, and helping to facilitate a more efficient review. As part of the readiness review, Terra plans to provide draft sections of its Preliminary Safety Analysis Report (PSAR) and Environmental Report to the NRC on a phased basis beginning in July 2026 through a secure electronic reading room. The Company has requested that NRC staff commence the readiness review in August 2026 to align with Terras planned SOLO Construction Permit Application submission later in the year. objective has always been to execute a disciplined regulatory strategy that reduces risk while advancing SOLO toward commercial deployment, said Alessandro Petruzzi, Co-Founder and Chief Executive Officer of Terra Innovatum. By initiating this readiness review, we are asking NRC staff to engage with our safety and environmental documentation before formal submittal, with the aim of strengthening the Construction Permit Application and maintaining momentum toward commercialization. The readiness review is part of Terra's broader regulatory engagement strategy and follows previously announced licensing milestones, including submission of Terras regulatory engagement plan, topical reports covering design, safety, fuel and operations, and acceptance by the NRC of the principal design criteria report for review. Terra continues to progress toward submission of the SOLO Construction Permit Application in 2026 and its objective of commercialization in 2028. Duyuru • Jul 03
Terra Innovatum Global N.V. Announces Appointment of Joanna Lohkamp as Independent Director, Effective July 1, 2026 Terra Innovatum Global N.V. announced the appointment of Joanna Lohkamp, Chief Executive Officer of Smart Wires, to its Board of Directors, effective July 1, 2026. Lohkamp brought more than 30 years of global operating and board leadership experience across technology, manufacturing, and infrastructure-oriented businesses. Lohkamp had served as Chief Executive Officer of Smart Wires since 2023, after joining the company’s Board of Directors in 2021. Prior to joining Smart Wires, Lohkamp served in senior executive roles including Managing Partner and Chief Financial & Operating Officer at NBBJ, President and Chief Operating Officer at Isonics Semiconductor, and leadership positions at Intel Corporation spanning finance, operations, manufacturing, leadership development, and mergers and acquisitions. In addition to her executive leadership experience, Lohkamp brought extensive public- and private-company board experience, including leadership roles on audit and risk, compensation, and nominating and governance committees. She was co-founder of the Better Boards Initiative, a nonprofit dedicated to advancing effective and diverse board practices. Lohkamp was a National Association of Corporate Directors (NACD) Board Leadership Fellow and held the NACD Directorship Certification®. She held an MBA from the UC Berkeley Haas School of Business, and a B.A. in International Relations from Stanford University. Board Change • Jun 30
Less than half of directors are independent There are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Peter Hastings is the most experienced director on the board, commencing their role in 2025. Independent Non-Executive Director Rex Jackson was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Duyuru • May 23
Terra Innovatum Global N.V. Receives Notice of Nasdaq Listing Non-Compliance Due to Delayed SEC Filings On May 19, 2026, Terra Innovatum Global N.V. (the “Company”) received an expected deficiency letter (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”) and as a result of remaining delinquent in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “Form 10-K”), as required for continued listing on The Nasdaq Global Select Market. The Notice has no immediate effect on the listing or trading of the Company's common stock on Nasdaq Global Select Market. In accordance with Nasdaq’s listing rules, the Company has until June 15, 2026, to submit a plan to regain compliance with respect to the filing requirements. If the Company submits a plan to Nasdaq and Nasdaq accepts the plan, Nasdaq can grant an exception of up to 180 calendar days from the due date of the filing of the 2025 Form 10-K (as extended pursuant to Rule 12b-25 under the Securities Act of 1933, as amended (the “Securities Act”)), or until October 12, 2026, to regain compliance. The Company intends to regain compliance with Nasdaq’s listing rules as soon as practicable. Duyuru • Apr 18
Terra Innovatum Global N.V. Receives Notice of Non-Compliance with Nasdaq Listing Rule On April 16, 2026, Terra Innovatum Global N.V. (the Company) received an expected deficiency letter (the Notice) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of its failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the Form 10-K), as required for continued listing on The Nasdaq Global Select Market. The Notice has no immediate effect on the listing or trading of the Company's common stock on Nasdaq Global Select Market. In accordance with Nasdaq's listing rules, the Company has 60 calendar days, or until June 15, 2026, to submit a plan to regain compliance with respect to the filing requirement. If the Company submits a plan to Nasdaq and Nasdaq accepts the plan, Nasdaq can grant an exception of up to 180 calendar days from the due date of the filing of the 2025 Form 10-K (as extended pursuant to Rule 12b-25 under the Securities Act of 1933, as amended (the Securities Act)), or until October 12, 2026, to regain compliance. The Company intends to regain compliance with Nasdaq's listing rules as soon as practicable. Duyuru • Apr 16
Terra Innovatum Global N.V. and Mersen Achieve Graphite Prototype Manufacturing and Validation Milestone to Support First Deployment of Solo Micro-Reactor Terra Innovatum Global N.V. and Mersen announced the successful production of a graphite reactor core prototype marking an important step in manufacturing readiness for its FOAK reactor deployment. The milestone highlights the companies’ collaboration in advancing next-generation nuclear technologies. It demonstrates also Terra Innovatum’s progress in converting supply chain preparation into manufacturing execution as it advances toward FOAK deployment and NOAK commercialization. The milestone builds on Terra Innovatum’s previously announced agreement with Mersen securing nuclear-grade graphite and procurement of critical materials required for SOLO FOAK deployment targeted for 2027 and NOAK commercialization beginning in 2028. Leveraging Mersen’s expertise in nuclear-grade materials, the companies successfully produced a graphite prototype (i.e. an engineering prototype) to support SOLO FOAK development. The graphite engineering prototype has been successfully manufactured to required tolerances, validating reactor system integration and readiness for scalable, serialized production. The development of this graphite engineering prototype represents a meaningful technical milestone in the realization of the SOLO reactor core. These components are designed to host critical systems and core elements that influence thermal performance, and overall system reliability. This work also establishes the procedures and quality standards required for repeatable manufacturing and scalable deployment. SOLO will offer a wide range of versatile applications, providing CO2-free, behind-the-meter, and off-grid power solutions for data centers, mini-grids serving remote towns and villages, and large-scale industrial operations in hard-to-abate sectors like cement production, oil and gas, steel manufacturing, and mining. It also has the ability to supply heat for industrial applications and other specialized processes, including water treatment, desalination and co-generation. Thanks to its modular design, SOLO can easily scale to deliver up to 1GW or more of CO2-free power with a minimal footprint, making it an ideal solution for rapidly replacing fossil fuel-based thermal plants. Beyond electricity and heat generation, SOLO can also contribute to critical applications in the medical sector by producing radioisotopes essential for oncology research and cancer treatment. 
